Skeletal effects of zoledronic acid in an animal model of chronic kidney disease

Osteoporosis International

Volumn 24, Issue 4, 2013, Pages 1471-1481

  Allen, M R ^a   Chen, N X ^a   Gattone II, V H ^a   Chen, X ^a   Carr, A J ^a   Leblanc, P ^a   Brown, D ^a   Moe, S M ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anti remodeling agents; Bisphosphonate; Bone mechanics; Remodeling suppression

Indexed keywords

CALCIUM; CREATININE; GLUCONATE CALCIUM; PARATHYROID HORMONE; PHOSPHORUS; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE MASS; BONE REMODELING; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORTICAL BONE; CREATININE CLEARANCE; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSSIFICATION; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RAT; SKELETON; TRABECULAR BONE; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BIOMECHANICAL PHENOMENA; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIAPHYSES; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMUR; IMIDAZOLES; MALE; OSTEOGENESIS; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY, CHRONIC; TIBIA;

EID: 84876460147     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2103-x     Document Type: Article

References (49)

1. Moe S, Dreke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945-1953
2. Sprague SM (2000) The role of the bone biopsy in the diagnosis of renal osteodystrophy. Semi Dial 13:152-155
3. Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, Kestenbaum BR, Stehman-Breen C (2002) Risk of hip fracture among dialysis and renal transplant recipients. JAMA 288:3014
4. Dooley AC, Weiss NS, Kestenbaum B (2008) Increased risk of hip fracture among men with CKD. Am J Kidney Dis 51:38-44
5. Jamal SA, West SL, Miller PD (2011) Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int 23:1191-1198
6. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - results from the fracture intervention trial. JAMA 280:2077-2082
7. Black DM, Cummings SR, Karpf DB et al (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
8. Reginster JY, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91
9. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age related reduced renal function as estimated by the cockcroft and gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20:2105-2115
10. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22:503-508
11. Matthew S, Lund RJ, Strebeck F, Tustison K, Gueurs T, Hruska K (2007) Reversal of the adynamic bone bisorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 18:122-130
12. Moe S, Radcliffe J, White K, Gattone V II, Seifert M, Chen X, Aldridge B, Chen N (2011) The pathophysiology of early stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. J Bone Miner Res 26:2672-2681
13. Gonzalez E, Lund R, Martin K, Mccartney J, Tondravi M, Sampath T, Hruska K (2002) Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. Kidney Int 61:1322-1331
14. Lund RJ, Davies M, Brown A, Hruska K (2004) Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol 15:359-369
15. Lomashvili KA, Monier-Faugere M-C, Wang X, Malluche HH, O'Neill WC (2009) Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 75:617-625
16. Jokihaara J, Pörsti IH, Kööbi P et al (2008) Treatment of experimental renal osteodystrophy with pamidronate. Kidney Int 74:319-327
17. Cowley B, Gudapaty S, Kraybill AL, Barash BD, Harding MA, Calvet JP, Gattone V (1993) Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 43:522-522
18. Moe SM, Chen NX, Seifert MF, Sinders RM, Duan D, Chen X, Liang Y, Radcliff JS, White KE, Gattone VH (2009) A rat model of chronic kidney disease-mineral bone disorder. Kidney Int 75:176-184
19. Cowley B (1996) Modification of disease progression in rats with inherited polycystic kidney disease. Am J Kidney Dis 27:865-879
20. Gasser JA, Ingold P, Venturiere A, Shen V, Green JR (2008) Long term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 23:544-551
21. Brouwers JEM, van Rietbergen B, Bouxsein ML (2008) Influence of early and late zoledronic acid administration on vertebral structure and strength in ovariectomized rats. Calcif Tissue Int 83:186-191
22. Ferreira A, Frazao JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S (2008) Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 19:405
23. Li X, Jee W, Ke H, Mori S (1991) Age-related changes of cancellous and cortical bone histomorphometry in female Sprague-Dawley rats. Cells Mater 1:25-25
24. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25:1468-1486
25. Turner CH, Burr DB (1993) Basic biomechanical measurements of bone - a tutorial. Bone 14:595-608
26. Fuchs RK, Allen MR, Condon KW, Reinwald S, Miller LM, McClenathan D, Keck B, Phipps RJ, Burr DB (2008) Strontium ranelate does not stimulate bone formation in ovariectomized rats. Osteoporos Int 19:1331-1341
27. Allen MR, Iwata K, Phipps R, Burr DB (2006) Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39:872-879
28. Recker RR, Kimmel DB, Dempster D, Weinstein RS, Wronski TJ, Burr DB (2011) Issues in modern bone histomorphometry. Bone 49:955-964
29. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry - standaridization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610
30. Spasovski G (2004) Bone biopsy as a diagnostic tool in the assessment of renal osteodystrophy. Int J Artif Organs 27:918
31. Malluche HH, Faugere MC (1986) Atlas of mineralized bone histology. S. Karger Pub, Basel, Switzerland
32. Andress DL, Maloney NA, Endres DB, Sherrard DJ (1986) Aluminum associated bone disease in chronic renal failure: high prevalence in a long term dialysis population. J Bone Miner Res 1:391-398
33. De Vernejoul M, Belenguer R, Halkidou H, Buisine A, Bielakoff J, Miravet L (1985) Histomorphometric evidence of deleterious effect of aluminum on osteoblasts. Bone 6:15-20
34. Heaf J (2000) Causes and consequences of adynamic bone disease. Nephron 88:97-106
35. Brandenburg VM, Floege J (2008) Adynamic bone disease: bone and beyond. NDT Plus 1:135-147
36. Recker RR, Delmas PD, Halse J et al (2008) Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6-16
37. Coco M (2003) Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 14:2669-2676
38. Smith SY, Recker RR, Hannan M, Muller R, Bauss F (2003) Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32:45-55
39. Weinstein RS, Roberson PK, Manolagas SC (2009) Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360:53-62
40. Miller PD (2011) The kidney and bisphosphonates. Bone 49:77-81
41. Seeman E, Delmas PD (2006) Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261
42. Iwasaki Y, Kazama JJ, Yamato H, Fukagawa M (2011) Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease. Bone 48:1260-1267
43. Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP (2001) Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 28:195-201
44. Wang X, Shen X, Li X, Agrawal CM (2002) Age-related changes in the collagen network and toughness of bone. Bone 31:1-7
45. Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D (2009) Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 20:887-894
46. Allen MR, Gineyts E, Leeming DJ, Burr DB, Delmas PD (2008) Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int 19:329-337
47. Moe SM, Seifert MF, Chen NX, Sinders RM, Chen X, Duan D, Henley C, Martin D, Gattone VH (2009) R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). Nephrol Dial Transplant 24:2371
48. Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe RI, Majima K, Aoki T, Nihei H (2004) Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44:680-688
49. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG (2010) Effect of alendronate on vascular calcification in CKD Stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 56:57-68